CompletedNCT00447278
A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents
Medication studyAges 6–16Multiple countries
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 16 years. Other eligibility criteria applied.
- Listed locations
- Brussels and 34 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 399
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Belgium, ...
- Age range
- From 6 Years to 16 Years
- Official registry ID
- NCT00447278
- Official title
Show the full official title
A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning Using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder in Treatment-Naïve Children and Adolescents
Recruitment & locations
CompletedBrussels, Belgium · Hoboken, Belgium · Leuven, Belgium
33 more locations
- Amiens, France
- Bordeaux, France
- Lyon, France
- Montpellier, France
- Paris, France
- Toulouse, France
- Tours, France
- Westside, Ireland
- Dublin, Ireland
- Messina, Italy
- Naples, Italy
- S.Vito Tagliamento, Italy
- San Donà di Piave, Italy
- Insurgentes Cuicuilco, Mexico
- Mexico City, Mexico
- Roma Sur, Mexico
- Bergen, Norway
- Fredrikstad, Norway
- Alicante, Spain
- Barcelona, Spain
- Donostia / San Sebastian, Spain
- Espluges de Llobregat, Spain
- Palma de Mallorca, Spain
- Pamplona, Spain
- Sabadell, Spain
- Valencia, Spain
- Adana, Türkiye
- Ankara, Türkiye
- Izmir, Türkiye
- Basildon, United Kingdom
- Wigan, United Kingdom
- Sheffield, United Kingdom
- Türkiye
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 16 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...